Teva sues FDA over marketing exclusivity loss for generic Cozaar
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has sued the US FDA because of its loss of first-filer marketing exclusivity on generic versions of Merck & Co's antihypertensives, Cozaar (losartan potassium) and Hyzaar (losartan plus hydrochlorothiazide).